Analysts Set Cara Therapeutics, Inc. (NASDAQ:CARA) PT at $2.32

Cara Therapeutics, Inc. (NASDAQ:CARA) has received an average rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $2.32.

Separately, StockNews.com initiated coverage on Cara Therapeutics in a research note on Sunday. They issued a “sell” rating on the stock.

Institutional Trading of Cara Therapeutics

An institutional investor recently bought a new position in Cara Therapeutics stock. Marquette Asset Management LLC purchased a new stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned 0.17% of Cara Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Price Performance

CARA opened at $0.27 on Wednesday. The stock has a market cap of $14.71 million, a PE ratio of -0.12 and a beta of 0.70. Cara Therapeutics has a 52 week low of $0.24 and a 52 week high of $1.40. The business’s fifty day simple moving average is $0.30 and its 200 day simple moving average is $0.45.

Cara Therapeutics (NASDAQ:CARA) last released its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. As a group, equities analysts anticipate that Cara Therapeutics will post -1.24 earnings per share for the current year.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.